- Physician Prescribed
- Discreet
- Delivered To Your Door
Tirzepatide
Your safety is our first priority. Learn more about key medication details, side effects, and other important info about your treatment.
Prescribing information
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Dyspepsia
- Injection site reactions
- Fatigue
- Hypersensitivity reactions
- Eructation
- Hair loss
- Gastroesophageal reflux disease
Get Started for $149
Then $249 per month • billed quarterly • 60mg
Important safety information
Tirzepatide Injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity:
- To reduce excess body weight and maintain weight reduction long term in:
- Adults with obesity
- Adults with overweight in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease)
- To treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Limitations of Use:
- Co-administration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended
- The safety and efficacy of coadministration with other products for weight management have not been established
- Tirzepatide has not been studied in patients with a history of pancreatitis
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether Tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors
Do not use TIRZEPATIDE if you:
Feature
- Have a personal or family history of medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with Diabetes (Type 1
- Have been diagnosed with pancreatitis or history of pancreatitis
- Have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
- Have a known allergy to tirzepatide/any other GLP-1 drug or any of the inactive ingredients in TIRZEPATIDE. Inactive ingredients include: sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH
- Have a history of suicidal attempts or active suicidal ideation
Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated
Severe Gastrointestinal Disease: Use may be associated with gastrointestinal adverse reactions, sometimes severe. Has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients
Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting adverse reactions that could lead to volume depletion
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported postmarketing with tirzepatide. If suspected, advise patients to promptly seek medical attention and discontinue TIRZEPATIDE
Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
Females of Reproductive Potential: Discontinue at least 2 months before a planned pregnancy because of the long half-life of TIRZEPATIDE
Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue TIRZEPATIDE
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor patients with a history of diabetic retinopathy for progression
Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue TIRZEPATIDE if symptoms develop
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.
We have 10,247+ happy customers
I had difficulty losing weight until...
Weight loss was difficult for me until i discovered body forward It really helped me shed the weight.
Jenni Z.
Verified Buyer
I had difficulty losing weight until...
Weight loss was difficult for me until i discovered body forward It really helped me shed the weight.
Jenni Z.
Verified Buyer
I had difficulty losing weight until...
Weight loss was difficult for me until i discovered body forward It really helped me shed the weight.
Jenni Z.
Verified Buyer
I had difficulty losing weight until...
Weight loss was difficult for me until i discovered body forward It really helped me shed the weight.
Jenni Z.
Verified Buyer
Side Effects
Most common side effects, reported in ≥ 5% of patients treated with TIRZEPATIDE are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease
To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
DRUG INTERACTIONS
TIRZEPATIDE delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications
USE IN SPECIFIC POPULATIONS
Step 1
Pregnancy
May cause fetal harm. When pregnancy is recognized, discontinue TIRZEPATIDE
Step 2
Females of Reproductive Potential
Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
Step 3
Females and Males of Reproductive Potential
Discontinue TIRZEPATIDE at least 2 months before a planned pregnancy because of the long half-life of TIRZEPATIDE
Frequently Asked Questions
How is Tirzepatide different from GLP1 or Tesamorelin?
Tirzepatide is the only treatment that activates both GIP and GLP-1 receptors. This allows it to reduce appetite and improve insulin sensitivity more effectively than GLP1. Unlike Tesamorelin, it doesn’t stimulate growth hormone or specifically target visceral fat.
Is Tirzepatide only for people with diabetes?
No. While Tirzepatide was originally developed for type 2 diabetes, it’s also shown powerful weight loss effects in non-diabetic individuals. Many patients using Tirzepatide for weight management do not have diabetes. It regulates blood sugar and reduces appetite, supporting fat loss regardless of your diagnosis. Your provider will determine if it’s a good fit based on your overall health and goals.
How much weight can I lose?
Clinical trials showed that recipients using weekly doses experienced a mean weight loss of up to 20% at 72 weeks.
Is Tirzepatide safe?
Tirzepatide is FDA-approved and prescribed by licensed doctors. Although rare, side effects are similar to other GLP-1s: nausea, constipation, or fatigue, especially in early stages.
Do I need to follow a strict diet?
You don’t need to follow a strict diet while taking Tirzepatide, but your results will be much better if you follow a healthy, structured eating plan.
How long does it take to see results?
Results are based on the individual and how well your body responds to the medication. It is important to know that weight loss picks up between 8–12 weeks for most once the body has shed water weight and acclimated to the protocol.
Choose Tirzepatide Today For Faster, Deeper Weight Loss
Tirzepatide
- Suppress appetite powerfully
- Improve body composition
- Improves insulin sensitivity and metabolic health
- Clinically proven
- Dual-pathway GLP-1/GIP activation
Get Started for $149
Then $249 per month • billed quarterly • 60mg
